CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $253,276 | +3.6% | 5,580 | +28.2% | 0.01% | -16.7% |
| Q2 2023 | $244,434 | -1.0% | 4,354 | +15.1% | 0.01% | -14.3% |
| Q3 2022 | $247,000 | +2.9% | 3,784 | -4.2% | 0.01% | +16.7% |
| Q2 2022 | $240,000 | -4.4% | 3,951 | -1.0% | 0.01% | 0.0% |
| Q1 2022 | $251,000 | -12.5% | 3,992 | +5.6% | 0.01% | 0.0% |
| Q4 2021 | $287,000 | -28.4% | 3,781 | +5.6% | 0.01% | -40.0% |
| Q3 2021 | $401,000 | -28.9% | 3,581 | +2.7% | 0.01% | -28.6% |
| Q2 2021 | $564,000 | +11.9% | 3,486 | -15.8% | 0.01% | 0.0% |
| Q1 2021 | $504,000 | -21.7% | 4,138 | -1.6% | 0.01% | -26.3% |
| Q4 2020 | $644,000 | +117.6% | 4,205 | +19.0% | 0.02% | +90.0% |
| Q3 2020 | $296,000 | -5.4% | 3,535 | -16.9% | 0.01% | -9.1% |
| Q2 2020 | $313,000 | +40.4% | 4,255 | +16.3% | 0.01% | +22.2% |
| Q4 2019 | $223,000 | +218.6% | 3,660 | +133.1% | 0.01% | +200.0% |
| Q3 2018 | $70,000 | +233.3% | 1,570 | +237.6% | 0.00% | +200.0% |
| Q1 2018 | $21,000 | – | 465 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |